Beta-adrenergic transgene gene therapy that boosts myocardial responsiveness—unlocking heart-failure treatment models.
This approach inserts transgenes into heart muscle cells to increase beta-adrenergic responsiveness, enhancing cardiac performance in mammalian hearts. The method targets the myocardium directly by modulating signaling pathways rather than providing repeated external stimulation. Previously, using the specific gene-therapy method and compositions required licensing from the assignee.
Develop beta-adrenergic pathway gene-therapy platforms for congestive heart failure and related cardiomyopathies.
The present invention relates to methods and compositions for enhancing cardiac function in mammalian hearts by inserting transgenes that increase beta-adrenergic responsiveness within the myocardium. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure.
Post a problem you're solving with this technology and connect with founders, investors, and researchers.